EAM Investors’s Acadia Pharmaceuticals ACAD Stock Holding History

EAM Investors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-38,555	Closed	-$1.87M	–	264
2020 Q2	$1.87M	Buy	+38,555	New	+$1.85M	0.41%	98
2020 Q1	–	Sell	-49,891	Closed	-$2.13M	–	206
2019 Q4	$2.13M	Buy	49,891 +2,329	+5%	+$101K	0.47%	71
2019 Q3	$1.71M	Buy	+47,562	New	+$1.44M	0.45%	88
2016 Q3	–	Sell	-66,537	Closed	-$2.16M	–	294
2016 Q2	$2.16M	Buy	+66,537	New	+$2.23M	0.32%	168
2014 Q2	–	Sell	-46,875	Closed	-$1.14M	–	320
2014 Q1	$1.14M	Sell	46,875 -2,460	-5%	-$62.2K	0.21%	276
2013 Q4	$1.23M	Sell	49,335 -30,005	-38%	-$708K	0.22%	247
2013 Q3	$2.18M	Sell	79,340 -72,715	-48%	-$1.52M	0.43%	60
2013 Q2	$2.76M	Buy	+152,055	New	+$2.09M	0.6%	28

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

EAM Investors's ACAD Position: Q3 2020 in Review

EAM Investors sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 38,555 shares — an estimated $1.87M sold.

EAM Investors first reported a position in ACAD in Q2 2013 and held it in 8 quarters. The position peaked at $2.76M in Q2 2013. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

EAM Investors reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
EAM Investors sold 38,555 Acadia Pharmaceuticals shares in Q3 2020, an estimated $1.87M.
EAM Investors first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 8 quarters.
EAM Investors's Acadia Pharmaceuticals position peaked at $2.76M in Q2 2013.
267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on EAM Investors's 13F filing for Q3 2020, filed 13 Nov 2020.